| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI) has entered into a supply agreement for dried flower with the medical division of German cannabis company Sanity Group. Through exports from its cultivation facility in Moncton, Organigram already services medical patients in Israel and Australia, and will now add Germany to its growing list of international markets.
Under the terms of the agreement, the company will provideindoor-grown dried flower product to Sanity Group and grant Sanity Group strain exclusivity on certain genetics.
“With the German cannabis industry slowly moving toward a recreational adult-use model, we are excited to begin solidifying our relationships with reputable medical cannabis product developers and distributors like Sanity Group,” stated Beena Goldenberg, CEO of Organigram. “We are committed to providing customers and medical patients in Australia, Israel, and now Germany, with high-quality cannabis, produced through industry-leading research, development and consumer-led insights.”
Finn Age Hänsel, managing director & founder of Sanity Group, stated: “We look forward to bringing Organigram’s high-quality indoor-grown flower to our German medical patients. Organigram consistently ranks as a leader in flower sales nationally in Canada and will be providing us with exclusivity on certain strains within the German market.”
Photo: Benzinga edit with photos by Matthias Zomer on Pexels and squarefrog on Pixabay
Related News
Organigram Shares Trading Lower On Q2 FY23 Revenue Growth Of 24% YoY
Revolutionizing Sustainable Cannabis Vaping, Greentank Technologies Closes $16.5M Series B
Organigram Accelerates Focus On Vapes With Strategic Investment In Greentank
